Exhibitor Registration |JW Grand Ballroom Foyer, Level 4

Registration |JW Grand Ballroom Foyer, Level 4

Internet Cafe and Office Zone |JW Grand Ballroom Foyer, Level 4

Sponsored by  

Exhibitor and Sponsor Reception (Invitation Only) |Pool View Terrace, Level 5

Welcome Reception |Congress Avenue Terrace, Level 5

Internet Cafe and Office Zone |JW Grand Ballroom Foyer, Level 4

Sponsored by  

Registration |JW Grand Ballroom Foyer, Level 4

General Breakfast |Griffin Hall, Level 2

Opening General Session |JW Grand Ballroom 5-6, Level 4

Welcome Address |JW Grand Ballroom 5-6, Level 4

John M. Gray, President and CEO, Healthcare Distribution Alliance

The Case for Disruptive Thinking |JW Grand Ballroom 5-6, Level 4

Society is transforming; advancing technologies are not only reshaping the ways we lead but rapidly reinventing the ways we work, live and connect. Instead of predictably replicating the success of the past, leaders must now embrace and navigate these new opportunities and the need for constant innovation. In this presentation, learn how being open to radical new solutions will require radically new ways of thinking, “leadering” and being.

Nancy Giordano, Strategic Futurist, Corporate Strategist, Play Big Inc.

Expo and Networking Break |Griffin Hall, Level 2

Sponsored by  

Concurrent Education Sessions – Group A

A1: FDA DSCSA Activities in 2017–2018 |JW Grand Ballroom 8, Level 4

Sponsored by    

Over the last year, FDA has held three public meetings; announced a “Listening Session”; published, and accepted public comments on, numerous draft guidances; and requested public input on many other DSCSA-related topics. This session will provide an overview of these activities and highlight key areas that may impact members of the supply chain. An opportunity for audience questions will be provided.

	Anita T. Ducca, Senior Vice President, Regulatory Affairs, Healthcare Distribution Alliance
	Michael J. Mazur, Director, Trade Operations, Pfizer Inc.
	Scott A. Mooney, Vice President, Distribution Operations, McKesson Corporation
	Chris Smith, Director of Federal Public Policy, National Association of Chain Drug Stores

A2: Break-Out Discussion with the Drug Enforcement Administration |JW Grand Ballroom 1-2, Level 4

(Closed to the media)

Sponsored by

Interact with DEA and discuss current topics in controlled substances regulation.

James A. Arnold, Section Chief, Liaison and Policy Section, Diversion Control Division, U.S. Drug Enforcement Administration (DEA)

A3: Leading Through Influence |JW Grand Ballroom 3-4, Level 4

Sponsored by  

Leadership is the art of positively influencing the attitudes and behaviors of others, and it takes place at every level in an organization. Rather than a disposition or personality trait, leadership is a collection of skills that can be practiced and honed to harness individual strengths, tap into the motivators of others and positively influence behavior. This session will provide perspective on what drives human motivation and behavior, how to capitalize on your unique strengths and the strengths of others and how to manage difficult personalities — all while maximizing your engagement and performance.

Anne Grady, President & CEO, Anne Grady Group

A4: The 340B Drug Pricing Program |JW Grand Ballroom 7, Level 4

This session will provide an update on current guidance and initiatives related to the 340B Drug Pricing Program as well as top-of-mind operational issues for distributors and manufacturers.

	Kathleen Dynan Black, MBA, Director, Government Strategy, Pfizer Inc.